Keywords
How to Cite
Abstract
While a world flooded with COVID 19 expects the success of massive vaccination programs, a new and dangerous syndrome of only three months old has been described. It strikes individuals that received adenovirus vector vaccines, resulting in thrombocytopenia and thrombosis with significant mortality. This article summarizes clinical, laboratory and therapeutic aspects of the disease as well as its impact on the people confidence in SARS-COV-2 vaccines.
References
2. Greinacher A, Thiele Th, Warkentin TE et al. Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. N Engl J Med. 2021; 384:2092-2101.
3. Scully M, Singh D, Lown R et al. Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination. N Engl J Med. 2021; 384:2202-2211.
4. Greinacher A, Selleng K , Warkentin TE. Autoimmune heparin-induced thrombocytopenia. J Thromb Haemost. 2017; 15:2099-114.
5. Lee EJ, Cines DB, Gernsheimer T et al. Thrombocytopenia following Pfizer and Moderna SARS-COV-2 vaccination. Am J Hematol. 2021; 1-4.
6. Greinacher A, Selleng K, Mayerle J et al. Anti -SARSCOV-2 Spike protein and Anti-Platelet Factor 4 Antibodies responses induced by COVID-19 Disease and ChAdOx1 nCOV-19 vaccination. Research Square. DOI: https://doi.org/10.21203/rs.3.rs-404769/v1
7. Hausberg Sorvoll et al. An observational study to identify the prevalence of thrombocytopenia and anti-PF4 /polyanion antibodies in Norwegian health care workers after COVID-19 vaccination. JTH in press.
8. Marchetti M, Zermatten MG, Bertaggia Calderara G et al. Heparin-Induced Thrombocytopenia: A Review
of New Concepts in Pathogenesis, Diagnosis, and Management. J Clin Med. 2021,10, 683. https://doi.org/10.3390/ jcm10040683.
9. Gollomp K, Kim M, Johnston I et al. Neutrophil accumulation and NET release contribute to thrombosis in HIT. JCI Insight. 2018;3(18):e99445. https://doi.org/10.1172/ jci.insight.99445.
10. Chan BT, Bobos P, Odutayo A et al. medRxiv preprint doi: https: //doi.org/ 10.1101/2021.05.04.21256613.
11. Scully M. VITT. ISTH Webinar 2021. 12. Taha M, Samavati L. Antiphospholipid antibodies in COVID-19: a meta-analysis and systematic review. RMD Open. 2021; 7(2): e001580.
13. Biggioggero M, Meroni PL. The geoepidemiology of the antiphospholipid antibody syndrome. Autoimmun Rev. 2010;9(5):A299-304.
14. Vassalo J, Spector N, de Meis, E et al. Antiphospholipid antibodies in critically ill patients. Rev Bras Ter Intensiva. 2014 Apr-Jun; 26(2): 176-182.
15. Arepally GM. Heparin-induced thrombocytopenia. Blood. 2017; 129(21): 2864-2872.
16. Cuker A, Arepally GM, Chong BH et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv. 2018 ; 2(22): 3360-3392.
17. Brodard, Kremer Hovinga JA, Fontana P et al. COVID-19 patients often show high- titer non-platelet-activating anti-PF4/heparin IgG antibodies. J Thromb Haemost. 2021; 10.1111/jth.15262. doi: 10.1111/jth.15262.
18. Goldman L, Duan R, Kragh Th, et al. Oral Bruton tyrosine kinase inhibitors block activation of the platelet
Fc receptor CD32 (Fcγ RIIA): a new option in HIT?. Blood Adv 2019; 23: 4021-4033
All material published in the journal HEMATOLOGÍA (electronic and print version) is transferred to the Argentinean Society of Hematology. In accordance with the copyright Act (Act 11 723), a copyright transfer form will be sent to the authors of approved works, which has to be signed by all the authors before its publication. Authors should keep a copy of the original since the journal is not responsible for damages or losses of the material that was submitted. Authors should send an electronic version to the email: revista@sah.org.ar